AngioDynamics Inc. reported fiscal‑year 2026 third‑quarter revenue of $78.4 million, surpassing the consensus estimate of $76.8 million by $1.6 million, a 2.1% beat. The lift was driven by a 19% year‑over‑year increase in the Med Tech segment, which now accounts for 48% of total sales compared with 44% in Q3 FY25, while the Med Device segment grew only 1.1%.
Adjusted earnings per share were $(0.07) versus the consensus expectation of $(0.11), a $0.04 improvement. The narrower loss reflects stronger operating leverage and a higher mix of high‑margin Med Tech products, offsetting a 110‑basis‑point contraction in GAAP gross margin to 52.9% from 53.9% in the prior year, largely due to tariff, inflation, and manufacturing transition costs.
Management raised its full‑year adjusted EPS guidance from a range of $(0.33) to $(0.23) to $(0.30) to $(0.23), marking the third consecutive quarter of upward revisions. The update signals confidence that the company’s strategic shift toward a high‑margin Med Tech platform will continue to deliver improved profitability.
Segment performance highlights that Med Tech revenue grew 19% YoY, driven by strong demand for Auryon, AngioVac, AlphaVac, and NanoKnife. Jim Clemmer, president and CEO, noted that the company “delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth.” He added that the mechanical thrombectomy portfolio “exhibited standout performance” and that NanoKnife is accelerating adoption following a new CPT 1 code for prostate.
Adjusted EBITDA rose to $1.8 million in Q3 FY26 from $1.3 million in Q3 FY25, a 38% year‑over‑year increase. The improvement is attributed to Med Tech revenue growth and operational efficiencies, even as gross margin contracted due to external cost pressures.
The results reinforce AngioDynamics’ trajectory toward profitability, with revenue growth and a tightening loss margin, and suggest that the company’s focus on high‑margin Med Tech products is paying off.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.